Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Gonzalo RecondoLaura MezquitaFrancesco FacchinettiDavid PlanchardAnas GazzahLudovic BigotAhsan Z RizviRosa L FriasJean-Paul ThieryJean-Yves ScoazecTony SourisseauKaren HowarthOlivier DeasDariia SamofalovaJustine GalissantPauline TessonFloriane BrayeCharles NaltetPernelle LavaudLinda MahjoubiAurélie Abou LovergneGilles VassalRastilav BahledaAntoine HollebecqueClaudio NicotraMaud Ngo-CamusStefan MichielsLudovic LacroixCatherine RichonNathalie AugerThierry De BaereLambros TselikasEric SolaryEric AngevinAlexander M EggermontFabrice AndreChristophe MassardKen A OlaussenJean-Charles SoriaBenjamin BesseLuc FribouletPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
This study shows that mechanisms of resistance to lorlatinib are diverse and complex, requiring new therapeutic strategies to tailor treatment upon disease progression.
Keyphrases